InsiderTrades

Form 4 for NTLA Intellia Therapeutics, Inc.

Accepted 2021-09-09 00:00:00 ET · period of report 2021-09-07 · accession 0001209191-21-055347 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2021-09-09 2021-09-07 NTLA Goddard Glenn EVP, CFO M - OptEx $14.58 +3,482 3,482 New +$50.8K
D 2021-09-09 2021-09-07 NTLA Goddard Glenn EVP, CFO S - Sale+OE $180.12 -3,482 0 -100% -$627.2K
D 2021-09-09 2021-09-07 NTLA Goddard Glenn EVP, CFO M - OptEx $0.00 -3,482 12.5K -22% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-09-07 M A 3,482 $14.58 3,482 D — —
2 Common Common Stock 2021-09-07 S D 3,482 $180.12 0 D — — (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.00 to $180.50, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 7, 2021 at each separate price.
3 Derivative Stock Option (right to buy) 2021-09-07 M D 3,482 $0.00 12,451 D $14.58 · — to 2028-12-17 3,482 Common Stock (F3) The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 11,833 shares as of September 7, 2021.